Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)

Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort

(2018) Nimish J. Thakore et al.   MUSCLE & NERVE

Prevalence of Amyotrophic Lateral Sclerosis — United States, 2014

(2018) Paul Mehta et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Amyotrophic Lateral Sclerosis

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis

(2017)   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

(2017) Koji Takei et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset

(2016) Malcolm Proudfoot et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Progression in ALS is not linear but is curvilinear

(2010) Paul H. Gordon et al.   JOURNAL OF NEUROLOGY